Dramatic response to crizotinib in a breast cancer patient with ALK gene rearrangement
ANTI-CANCER DRUGS, vol.33, pp.400-405, 2022 (SCI-Expanded, Scopus)
- Publication Type: Article / Case Report
- Volume: 33
- Publication Date: 2022
- Doi Number: 10.1097/cad.0000000000001272
- Journal Name: ANTI-CANCER DRUGS
- Journal Indexes: Scopus, Science Citation Index Expanded (SCI-EXPANDED), BIOSIS, Biotechnology Research Abstracts, Chemical Abstracts Core, EMBASE, CAB Abstracts, MEDLINE, Veterinary Science Database
- Page Numbers: pp.400-405
- Akdeniz University Affiliated: Yes
Abstract
Rearrangements of the anaplastic lymphoma kinase (ALK) gene are present in 3-5% of non-small-cell lung cancer (NSCLC), while it was 0.2% in NSCLC tumors. Due to its low frequency, it is extremely challenging to conduct randomized clinical trials of ALK-targeted therapies in NSCLC tumors. In the present case, we describe the first reported case of triple-negative breast cancer (TNBC) harboring the ALK fusion mutation that responded to ALK-targeted therapy after progression with two lines of chemotherapy. Searching for ALK gene rearrangement or other fusion, especially in patients with chemotherapy-resistant TNBC, opens the door to new treatment strategies.